Focusing on the real-world impacts of neglecting Extreme Value Theory (EVT), particularly in biotechnology and pharmaceuticals, offers a potent narrative.

The biotech world thrives on optimism. Pitch decks brimming with breakthroughs and life-saving treatments are a staple of the industry’

The Problem with Probability of Phase Transition (POPT) in Biotech and Pharma Probability of Phase Transition (POPT) is a commonly

Biotech investments are uniquely characterized by uncertainty, where extreme events—whether unexpected breakthroughs or catastrophic failures—play an outsized role.

Every year, large corporations—especially in pharma and biotech—proudly announce new startup accelerators, innovation challenges, or early-stage grant programs

Hazard ratios (HRs) are a widely used measure in survival analysis, summarizing the relative risk of an event occurring in

In drug development, where uncertainty reigns supreme and success often feels as elusive as a pot of gold at the

Amongst biotech funding options, royalty financing sits as the misunderstood sibling: alluring but mysterious, promising much yet carrying hidden risks.

Biotechnology operates at the confluence of intricate scientific inquiry and uncertain financial markets. Drug discovery, clinical trials, and regulatory approvals

Value at Risk (VaR) is a financial metric designed to quantify the maximum expected loss of an investment portfolio over